erectile%20dysfunction
ERECTILE DYSFUNCTION

Erectile dysfunction is the inability to attain and maintain an erection enough to have satisfactory sexual performance for ≥3 months.

It is when the patient complains of partial erection that could not attain vaginal penetration.

Complete loss of penile rigidity is uncommon.

Initial penile erections can penetrate but early detumescence occurs without ejaculation.

Surgical Intervention

Penile Vascular Surgery

  • Arterial reconstructive surgery should be considered only in healthy men w/ recently acquired erectile dysfunction due to a focal arterial occlusion in the absence of a generalized vascular disease

Penile Drug Delivery (Implanted) Devices

  • May be tried before standard implants are used if erection is possible w/ pharmacological injection

Penile Implants

  • Considered final treatment for erectile dysfunction patients & should be reserved for patients who have failed other treatments
  • Irreversible & highly invasive
  • When performed by experienced surgeon has been associated w/ high rate of patient satisfaction
  • May have surgical complication & mechanical failure
  • Available classes of penile implants are inflatable (2- & 3- piece) & malleable devices
  • Surgical approaches include penoscrotal & infrapubic
Editor's Recommendations
Most Read Articles
Stephen Padilla, 5 days ago
The novel coronavirus disease (COVID-19) pandemic appears to have a significant impact on oncological care, according to a study, which stresses the need for psycho-oncological support for cancer patients.
01 Aug 2020
Supplementation with probiotics may have positive effects in patients with type 2 diabetes mellitus (T2DM), reports a recent meta-analysis.
5 days ago
Sodium–glucose cotransporter-2 (SGLT-2) inhibitors increase the risk for diabetic ketoacidosis (DKA) by almost threefold, with molecule-specific analyses suggesting a class effect, according to a study.
Jairia Dela Cruz, 03 Aug 2020
In the first year following percutaneous coronary intervention for acute coronary syndrome, ticagrelor and prasugrel cuts the risk of gastrointestinal (GI) bleeding by more than 30 percent compared with clopidogrel, as shown in a large real-world study.